X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2941) 2941
Newsletter (210) 210
Publication (176) 176
Book Review (32) 32
Book Chapter (25) 25
Newspaper Article (24) 24
Magazine Article (15) 15
Dissertation (3) 3
Trade Publication Article (3) 3
Conference Proceeding (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
omalizumab (2889) 2889
humans (1778) 1778
index medicus (1293) 1293
asthma (1154) 1154
allergy (1122) 1122
immunology (940) 940
female (738) 738
asthma - drug therapy (731) 731
male (688) 688
adult (634) 634
immunoglobulin e (572) 572
antibodies, monoclonal, humanized (561) 561
antibodies, monoclonal - therapeutic use (533) 533
middle aged (526) 526
anti-asthmatic agents - therapeutic use (511) 511
treatment outcome (509) 509
antibodies, anti-idiotypic (458) 458
anti-allergic agents - therapeutic use (422) 422
antibodies, anti-idiotypic - therapeutic use (402) 402
ige (397) 397
immunoglobulin e - immunology (387) 387
urticaria (386) 386
child (356) 356
immunotherapy (350) 350
omalizumab - therapeutic use (347) 347
antibodies, monoclonal, humanized - therapeutic use (341) 341
adolescent (340) 340
anti-ige (335) 335
therapy (331) 331
asthma - immunology (328) 328
efficacy (325) 325
care and treatment (318) 318
allergies (309) 309
monoclonal antibodies (305) 305
respiratory system (304) 304
quality of life (299) 299
children (292) 292
drug therapy (292) 292
aged (271) 271
allergy and immunology (270) 270
dermatology (270) 270
immunoglobulin e - blood (262) 262
urticaria - drug therapy (258) 258
chronic disease (254) 254
patients (249) 249
research (245) 245
animals (242) 242
double-blind (242) 242
severity of illness index (240) 240
quality-of-life (238) 238
anti-ige antibody (215) 215
medical research (207) 207
young adult (207) 207
inflammation (201) 201
safety (191) 191
medicine, experimental (187) 187
abridged index medicus (181) 181
asthma - physiopathology (176) 176
analysis (172) 172
management (172) 172
pharmacology & pharmacy (172) 172
diagnosis (171) 171
medicine, general & internal (170) 170
severe asthma (169) 169
fc-epsilon-ri (167) 167
exacerbations (160) 160
monoclonal-antibody (160) 160
internal medicine (156) 156
severe allergic-asthma (156) 156
anti-asthmatic agents - adverse effects (153) 153
asthma - therapy (153) 153
allergic-asthma (151) 151
chronic idiopathic urticaria (148) 148
mepolizumab (148) 148
clinical trials (145) 145
pediatrics (142) 142
adrenal cortex hormones - therapeutic use (141) 141
medicine & public health (141) 141
anti-asthmatic agents - administration & dosage (140) 140
anaphylaxis (137) 137
rhinitis (131) 131
allergens (129) 129
antibodies, monoclonal - administration & dosage (129) 129
chronic spontaneous urticaria (129) 129
antihistamines (127) 127
asthma - diagnosis (127) 127
studies (127) 127
antibodies, monoclonal - adverse effects (126) 126
dosage and administration (123) 123
allergens - immunology (122) 122
severe persistent asthma (122) 122
allergic rhinitis (121) 121
dermatitis (120) 120
allergic asthma (119) 119
chronic urticaria (118) 118
corticosteroids (118) 118
food allergy (116) 116
expression (114) 114
double-blind method (110) 110
biomarkers (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2825) 2825
German (100) 100
French (92) 92
Spanish (48) 48
Italian (34) 34
Polish (32) 32
Japanese (25) 25
Korean (16) 16
Portuguese (11) 11
Czech (7) 7
Turkish (7) 7
Chinese (6) 6
Danish (4) 4
Russian (4) 4
Dutch (3) 3
Hebrew (2) 2
Hungarian (2) 2
Slovenian (2) 2
Swedish (2) 2
Croatian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Biological Chemistry, ISSN 0021-9258, 06/2017, Volume 292, Issue 24, pp. 9975 - 9987
Immunoglobulin E and its interactions with receptors Fc is an element of RI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved... 
RECEPTOR COMPLEXES | DOMAIN | FC-EPSILON-RI | CONFORMATIONAL-CHANGES | AFFINITY | CRYSTAL-STRUCTURE | BENT | BIOCHEMISTRY & MOLECULAR BIOLOGY | MONOCLONAL-ANTIBODY | MAMMALIAN-CELLS | BINDING | Surface Plasmon Resonance | Omalizumab - genetics | Recombinant Fusion Proteins - pharmacology | Immunoglobulin Fc Fragments - metabolism | Humans | Omalizumab - metabolism | Crystallography, X-Ray | Recombinant Fusion Proteins - metabolism | Receptors, IgE - chemistry | Immunoglobulin E - genetics | Immunoglobulin Fab Fragments - metabolism | Fluorescence Resonance Energy Transfer | Protein Interaction Domains and Motifs | Recombinant Proteins - metabolism | Anti-Asthmatic Agents - pharmacology | Omalizumab - chemistry | Pliability | Immunoglobulin Fab Fragments - genetics | Immunoglobulin E - metabolism | Protein Refolding | Solubility | Models, Molecular | Receptors, IgE - antagonists & inhibitors | Recombinant Proteins - chemistry | Immunoglobulin Fc Fragments - chemistry | Recombinant Fusion Proteins - chemistry | Recombinant Proteins - pharmacology | Immunoglobulin Fab Fragments - pharmacology | Immunoglobulin E - chemistry | Point Mutation | Receptors, IgE - metabolism | Immunoglobulin Fab Fragments - chemistry | Omalizumab - pharmacology | Allosteric Site | Immunoglobulin Fc Fragments - pharmacology | Protein Conformation | Immunoglobulin Fc Fragments - genetics | Amino Acid Substitution | X-ray crystallography | Immunology | antibody | immunoglobulin E (IgE) | allergy | omalizumab | allosteric regulation
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2015, Volume 136, Issue 6, pp. 1476 - 1485
Journal Article
Journal Article
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 04/2017, Volume 69, Issue 4, pp. 872 - 872
Journal Article
Respiratory Medicine, ISSN 0954-6111, 11/2019, Volume 159, p. 105804
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 01/2015, Volume 135, Issue 1, pp. 67 - 75
ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy... 
DIAGNOSIS | THERAPY | ANTI-IGE OMALIZUMAB | CHRONIC IDIOPATHIC URTICARIA | DERMATOLOGY
Journal Article
Journal Article
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, ISSN 1610-0379, 05/2019, Volume 17, pp. 12 - 15
Journal Article